Reuters (7/20, Chander, D’Silva) reports that the FDA has “accepted Acadia Pharmaceuticals Inc’s application for an antipsychotic drug to treat dementia patients with hallucinations and delusions.” The medication, “Nuplazid [pimavanserin], was approved in the United States in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.” (SOURCE: APA Headlines)